Krustat (Simvastatin)

Simvastatin inhibits HMG‑CoA reductase, the key enzyme in the hepatic synthesis of cholesterol. By blocking this step, intracellular cholesterol falls, prompting liver cells to increase LDL‑receptor expression, which clears more LDL cholesterol from the bloodstream and lowers overall plasma cholesterol.

The appropriate dose of Krustat is determined by the prescribing healthcare professional based on the patient’s lipid profile, cardiovascular risk, and tolerance. Dosage may be adjusted over time to achieve target cholesterol levels while monitoring for safety.

Simvastatin is generally contraindicated during pregnancy and lactation because cholesterol synthesis is essential for fetal development. It should only be used if the potential benefit justifies the potential risk, and this decision must be made by a qualified prescriber.

To order Krustat, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Krustat (simvastatin) is a moderate‑intensity statin, offering effective LDL‑cholesterol reduction comparable to other agents in its class. Compared with higher‑potency statins such as atorvastatin or rosuvastatin, simvastatin may require higher doses to achieve similar lipid‑lowering effects, but it also has a well‑established safety profile.

Krustat tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Krustat is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it.

The most serious adverse reactions include rhabdomyolysis, a severe muscle breakdown that can lead to kidney failure, and significant liver enzyme elevations indicating hepatic injury. Promptly report unexplained muscle pain, weakness, or dark urine, and have liver function tested regularly.

Krustat should not be used by individuals with active liver disease, unexplained persistent elevations of transaminases, or known hypersensitivity to simvastatin or any tablet excipients. It is also contraindicated in patients taking strong CYP3A4 inhibitors that cannot be discontinued.